







It is our right
to be seen
and heard!

Donate!
Provide
support

Join
Us!
Become
a team member.

“It is amazing what you can accomplish if you do not care who gets the credit.”
Harry S Truman 1884-
MULTIPLE
SCLEROSIS
Comparison of 2,538 proteins from MS patients with those from healthy brains showed damage in two proteins not before linked to the disease.
In mice blocking the effects of the proteins led to reversal of symptoms, the study in Nature reported.
Study leader Professor Lawrence Steinman said this was the first large-
But two in particular -
These normally participate in the control of blood clotting and in anti-
Treatment
Professor Steinman, from Stanford University School of Medicine in California, said the finding opened up the way for new treatments.
However, using existing drugs which interfere with the control of blood clotting would be dangerous because of an increased risk of bleeding.
Professor Neil Scolding, from the University of Bristol Institute of Clinical Neurosciences, said: "From the scientific perspective, the exciting thing is that it's pretty much the first time that proteomics has directly yielded a candidate molecule that is both unexpected and novel on the one hand and has therapeutic potential.
"From the clinical perspective, showing that treatment approaches predicted by this proteomic interrogation of MS tissue do have a clear impact in experimental models of MS is extremely promising.
"This points the way to a new area of MS research of considerable interest, and which could well lead in the future to new lines of treatment."
"This is early research but provides an interesting insight into some of the potential players that cause different types of damage to the central nervous system in people with MS.
"Understanding how MS develops is vital to target therapies for the condition."
Source BBC news.bbc.co.uk
A recent study suggested that people already infected with this kind of worm, known as helminths, experienced fewer symptoms of MS. This has led the FDA to approve a small trial of the therapy next month on five patients.
It is hoped that the therapy will prove to be a useful treatment with few of the side effects associated with some other MS treatments. Similar therapies have proved useful in treating some sufferers of inflammatory bowel disease.
Sources: ABC News March 17, 2008
====================
RESEARCH